Philip Dawson active positions
| Companies | Position | Start | End |
|---|---|---|---|
Elsie Biotechnologies Inc.
 Elsie Biotechnologies Inc. BiotechnologyHealth Technology Part of GSK Plc, Elsie Biotechnologies Inc. is a private biopharmaceutical company dedicated to unlocking the full potential of oligonucleotide therapeutics. The company is based in San Diego, CA. Elsie Biotechnologies integrates discovery, development, and delivery to increase potency, decrease toxicity, and optimize delivery of oligonucleotide therapeutics. The company's platform accesses the entire oligonucleotide chemistry space to optimize gene silencing and splice switching, and develops novel oligonucleotide therapeutics that are more potent, safer, and easier to deliver to target tissues. Elsie Biotechnologies is focused on unlocking the full potential of RNA therapeutics to treat undruggable diseases. The company was founded in 2021 by Phil Baran and Philip E. Dawson. The CEO is Kevin Green. Elsie Biotechnologies was acquired by GSK Plc on June 06, 2024 for $50 million. | Director/Board Member | 31/12/2020 | - |
| Founder | 31/12/2020 | - |
Career history of Philip Dawson
Statistics
International
| United States | 2 |
Operational
| Director/Board Member | 1 |
| Founder | 1 |
Sectoral
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
Elsie Biotechnologies Inc.
Elsie Biotechnologies Inc. BiotechnologyHealth Technology Part of GSK Plc, Elsie Biotechnologies Inc. is a private biopharmaceutical company dedicated to unlocking the full potential of oligonucleotide therapeutics. The company is based in San Diego, CA. Elsie Biotechnologies integrates discovery, development, and delivery to increase potency, decrease toxicity, and optimize delivery of oligonucleotide therapeutics. The company's platform accesses the entire oligonucleotide chemistry space to optimize gene silencing and splice switching, and develops novel oligonucleotide therapeutics that are more potent, safer, and easier to deliver to target tissues. Elsie Biotechnologies is focused on unlocking the full potential of RNA therapeutics to treat undruggable diseases. The company was founded in 2021 by Phil Baran and Philip E. Dawson. The CEO is Kevin Green. Elsie Biotechnologies was acquired by GSK Plc on June 06, 2024 for $50 million. | Health Technology |
- Stock Market
- Insiders
- Philip Dawson
- Experience
